Comparison Between Ultrasound-Guided Genicular Nerve Phenol Neurolysis and Intra-articular Steroid Injections
Unknown statusPhase 4NCT06000709
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Genicular nerve neurolysis (GN) constitutes a relatively novel technique, whereby different chemical compounds (i.e. alcohol, phenol) are injected in close proximity to the genicular nerves of the knee joint, with the intention to exert a neurolytic effect by denaturing proteins resulting in Wallerian degeneration distal to the lesion. Based on the preliminary evidence and considering the potential benefits of the technique, we hypothesized that ultrasound-guided genicular chemical neurolysis with phenol is superior in terms of pain relief at 3 months, when compared to intra-articular steroid (IAS) injection.
Study details
- Official title
- Randomized, Double-blinded, Comparison Between Ultrasound-Guided Genicular Nerve Phenol Neurolysis and Intra-articular Steroid Injections
- Conditions
- Interventions
- Drug: 6% aqueous phenol
- Drug: MethylPREDNISolone 40 MG
- Drug: Intraarticular Knee Placebo
- Drug: Genicular Nerve Placebo
- Sponsor
- University of Manitoba
- Start date
- 2023-10-20
- Primary completion
- 2024-01-31
- Sex
- All
- Age range
- from 40 Years to 80 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Severe knee pain for more than 6 months, defined as Numeric rating scale (NRS) score of 6 and greater, unresponsive to conservative medical treatment * Radiological OA grade 2 to 4 (Kellgren-Lawrence scale) Exclusion Criteria: * Previous total knee replacement on the index knee * Prior knee radiofrequency ablation on the index knee * Connective tissue diseases with knee involvement (e.g. rheumatoid arthritis) * Body mass index ≥ 40 kg/m2 * Uncontrolled coagulopathy, defined as supratherapeutic dose of anticoagulation medication * Allergy to local anesthetics * Unstable opioid consumption, defined as an increase \>10% in dosage during the last 3 months prior to recruitment.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06000709